Caricamento...

Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer

Chemotherapy has historically proven toxic and ineffective for the treatment of metastatic hormone-refractory prostate cancer (HRPC), a disease with substantial morbidity and mortality. Progress has been made in symptom relief, and the combination of mitoxantrone and prednisone is considered the pal...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autore principale: Petrylak, Daniel P
Natura: Artigo
Lingua:Inglês
Pubblicazione: MedReviews, LLC 2003
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1502327/
https://ncbi.nlm.nih.gov/pubmed/16986041
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !